TD says Spyre has ‘superior TL1A program’ after Teva data

TD Cowen analyst Tyler Van Buren recommends buying shares of Spyre Therapeutics (SYRE) following the “impressive results” from Teva (TEVA) and Sanofi (SNY) in inflammatory bowel diseases. Similar to its bigger rivals, Spyre has an anti-TL1A monoclonal antibody in its product pipeline, known as SPY002, the analyst tells investors in a research note. TD believes Spyre has the “superior TL1A program” and its combination treatments under development “will further elevate outcomes.” Teva and Sanofi’s results “further validate TL1A inhibition as a highly promising mechanism” for both ulcerative colitis and Crohn’s disease, contends the firm.